HGHVX Mutual Fund

HGHVX Mutual Fund

NAV$57.63
See how much of HGHVX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Aug 31, 2026

Net Assets
$7M
Expense Ratio
0.92%
Dividend Yield (Current)
-
Holdings
83
Inception Date
Feb 28, 2019
Fund Family
Hartford Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+15.12%
1 Year+25.64%
3 Year+14.88%
5 Year+4.66%
10 Year+10.74%

Asset Allocation

Stocks: 99.79%
Other: 0.21%
See how much of HGHVX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co11.62%
JNJJohnson & Johnson - Common6.71%
MRKMerck & Company Inc6.42%
ABBVAbbvie Inc.4.33%
UNHUnitedhealth Group Incorporated4.27%
Top 10 Concentration: 47.14%Report Date: Aug 31, 2026
Download all 83 holdings for HGHVX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Annually
Latest Distribution
$4.37
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

HGHVX Mutual Fund Overview

HGHVX Mutual Fund (The Hartford Healthcare Fund Class R6) is managed by Hartford Funds with $6.5M in net assets. HGHVX expense ratio is 0.92%, holding 83 positions across sectors including Health Care, Financials, Information Technology. Inception date: 2019-02-28.

HGHVX performance shows a YTD return of 15.12%. The 1-year return is 25.64% and the 5-year return is 4.66%.

HGHVX top holdings include Eli Lilly & Co (11.6%), Johnson & Johnson - Common (6.7%), Merck & Company Inc (6.4%), Abbvie Inc. (4.3%), Unitedhealth Group Incorporated (4.3%). Go to all HGHVX holdings, HGHVX sectors, or HGHVX dividends.

HGHVX can be compared against other funds. Use HGHVX overlap to find shared positions, or HGHVX vs another fund for a side-by-side view. HGHVX alternatives are available via the screener, along with tax-loss harvesting opportunities.